• 1
    Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporine. Transplant Proc 1991; 23: 29772983.
  • 2
    Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy, a clinical pathologic study of 96 patients. Transplantation 1992; 53: 10561062.
  • 3
    U.S. Multicenter FK506 Liver Study Group. Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679688.
  • 4
    McCauley J, Takaya S, Fung J, Tzakis A, Abu-Elmagd K, Jain A, Todo S, et al. The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 1991; 23: 14441447.
  • 5
    Alessiani M, Kusne S, Martin M, Jain A, Abu-Elmagd K, Moser J, Todo S, et al. Infections in adult liver transplant patients under Fk506 immunosuppression. Transplant Proc 1991; 23: 15011503.
  • 6
    Shapiro R, Fung JJ, Jain AB, Parks S, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990; 22: 3536.
  • 7
    SteinmullerDR, ed. FK506 and Organ Transplantation. Austin: R.G. Landes Co., 1994.